Between September 2017 and February 2018, influenza A(H1N1)pdm09, A(H3N2) and B viruses (mainly B/Yamagata, not included in 2017/18 trivalent vaccines) co-circulated in Europe. Interim results from five European studies indicate that, in all age groups, 2017/18 influenza vaccine effectiveness was 25 to 52% against any influenza, 55 to 68% against influenza A(H1N1)pdm09, -42 to 7% against influenza A(H3N2) and 36 to 54% against influenza B. 2017/18 influenza vaccine should be promoted where influenza still circulates.
Interim 2017/18 influenza seasonal vaccine effectiveness: Combined results from five European studies / M. Rondy, E. Kissling, H. Emborg, A. Gherasim, R. Pebody, R. Trebbien, F. Pozo, A. Larrauri, J. Mcmenamin, M. Valenciano, B. Kaic, S.K. Filipovic, V. Visekruna-Vucina, I.P. Novosel, Z. Lovric, G. Petrović, T.G. Krause, T.K. Fische, B. Lina, A. Falchi, A. Vilcu, C. Souty, T. Blanchon, S. van der Werf, V. Enouf, S. Behillil, M. Valette, S. Bernard-Stoecklin, D. Lévy-Bruhl, O. Launay, P. Loulergue, N. Lenzi, Z. Lesieur, A. L’Honneur, F. Galtier, C. Agostini, C. Serrand, C. Merle, V. Foulongne, P. Vanhems, F. Lainé, G. Lagathu, F. Carrat, S. Buda, U. Preuss, K. Prahm, B. Schweiger, M. Wedde, A. Heider, M. Martin, B. Biere, R. Duerrwald, L. Domegan, L. Coughlan, J. O’Donnell, M. Joyce, C. Collins, L. Dunford, J. Moran, G. Tuite, M. Duffy, J. Connell, C. de Gascun, C. Rizzo, A. Bella, V. Alfonsi, M.R. Castrucci, S. Puzelli, E. Pagani, V. Ghisetti, E. Pariani, F. Baldanti, G. Palù, P. D’Agaro, F. Ansaldi, P. Affanni, G.M. Rossolini, B. Camilloni, P. Bagnarelli, M. Sanguinetti, L. Atripaldi, M. Chironna, C. Serra, F. Vitale, M. Chironna, C. Germinario, A. Orsi, F. Ansaldi, I. Manini, E. Montomoli, C. Napoli, G.B. Orsi, I. Casado, J. Castilla, L. Fernandino, I. Martínez-Baz, G. Ezpeleta, A. Navascués, A. Pérez-García, A. Aguinaga, C. Ezpeleta, A. Meijer, S. van den Brink, W. van der Hoek, G. Goderski, L. Wijsman, M. Bagheri, F. Dijkstra, M. de Lange, T. Marzec, P. Overduin, A. Teirlinck, E. Wentink, G. Donker, S. Marbus, R. van Gageldonk-Lafeber, P. Schneeberger, J.J. van Oosterheert, V. Schweitzer, G. Groeneveld, B. Nunes, A. Machado, A.P. Rodrigues, V. Gomez, I. Kislaya, R. Guiomar, P. Pechirra, P. Cristóvão, I. Costa, A. Panarra, R. Côrte-Real, J. Poças, M.J. Peres, L.G. Comas, M.E.I. Marisquerena, J.C. Galán, M.D. Folgueira, F.G. Carril, R.S. Martínez, G. Cilla, J. Castilla, M.G. Cenoz, C.Q. Rubio, E.M. Ochoa, M. Blasco, J.G. Duran, J.M. Vanrell, J. Reina, D. Castrillejo, A.M. Gherasim, C. Delgado, J. Oliva, I. Casas, M. García, M. Latorre, A.M.M. Beamonte, A.M. Sapiña, M.O. Amores, A. Aizpurúa, M. Montes, K. Zakikhany, M. Brytting, Å. Wiman, A. Carnahan, F. Warburton, A. Djennad, J. Ellis, N. Andrews, D. Marques, S. Cottrell, A. Reynolds, R. Gunson, M. Galiano, A. Lackenby, C. Robertson, M. O’Doherty, M. Sinnathamby, I. Yonova, C. Moore, M. Sartaj, S. de Lusignan, M. Zambon, A. Moren, P. Penttinen. - In: EUROSURVEILLANCE. - ISSN 1025-496X. - 23:9(2018 Mar 01). [10.2807/1560-7917.ES.2018.23.9.18-00086]
Interim 2017/18 influenza seasonal vaccine effectiveness: Combined results from five European studies
E. Pariani;
2018
Abstract
Between September 2017 and February 2018, influenza A(H1N1)pdm09, A(H3N2) and B viruses (mainly B/Yamagata, not included in 2017/18 trivalent vaccines) co-circulated in Europe. Interim results from five European studies indicate that, in all age groups, 2017/18 influenza vaccine effectiveness was 25 to 52% against any influenza, 55 to 68% against influenza A(H1N1)pdm09, -42 to 7% against influenza A(H3N2) and 36 to 54% against influenza B. 2017/18 influenza vaccine should be promoted where influenza still circulates.
| File | Dimensione | Formato | |
|---|---|---|---|
|
eurosurv-23-9-1.pdf
accesso aperto
Tipologia:
Publisher's version/PDF
Dimensione
532.52 kB
Formato
Adobe PDF
|
532.52 kB | Adobe PDF | Visualizza/Apri |
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
